---
figid: PMC5000752__ijms-17-01357-g007
figtitle: Simplified representation of canonical and non-canonical Hedgehog(HH) signaling
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5000752
filename: ijms-17-01357-g007.jpg
figlink: /pmc/articles/PMC5000752/figure/ijms-17-01357-f007/
number: F7
caption: Simplified representation of canonical and non-canonical Hedgehog(HH) signaling.
  Canonical activation of the HH pathway. (A) In the absence of HH ligand, PTCH1 present
  in the primary cilium prevents Smoothened (SMO) trafficking and localization to
  the cilia. GLI mediators are in complex with proteins, including protein kinase
  A (PKA) and suppressor of fused homolog (SUFU), and generate repressor GLI forms,
  which translocate to the nucleus and inhibit transcription of HH signaling target
  genes; (B) In the presence of HH ligand, ligand binding to PTCH1 leads to PTCH1
  internalization and degradation, SMO can traffic to the cilium and initiate a signaling
  cascade that processes the GLI proteins into transcriptional activator forms, which
  translocate to the nucleus and activate the expression of HH signaling target genes;
  (C) Activation of GLI1 and GLI2 in breast cancer by non-canonical pathways. Regulatory
  signaling cascades or regulatory proteins other than canonical Hedgehog signaling
  can modulate GLI1 and GLI2 expression, transcriptional activity and stability. Transforming
  growth factor β/transforming growth factor receptor (TGFβ/TGFR) signals can induce
  transcriptional up-regulation of GLI1 and GLI2 via SMAD. Receptor tyrosine kinases
  (RTK) signals via the PI3K-AKT signaling cascade can induce stabilization of the
  GLI1 protein. In ERα-positive breast cancer cells E2 induces expression of SHH and
  GLI1 independent of SMO activity. WNT signaling activation stimulates GLI2. GLI2
  ACT, the activator form of GLI2.
papertitle: 'Tamoxifen Resistance: Emerging Molecular Targets.'
reftext: Milena Rondón-Lagos, et al. Int J Mol Sci. 2016 Aug;17(8):1357.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9683792
figid_alias: PMC5000752__F7
figtype: Figure
redirect_from: /figures/PMC5000752__F7
ndex: 51060e37-decb-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5000752__ijms-17-01357-g007.html
  '@type': Dataset
  description: Simplified representation of canonical and non-canonical Hedgehog(HH)
    signaling. Canonical activation of the HH pathway. (A) In the absence of HH ligand,
    PTCH1 present in the primary cilium prevents Smoothened (SMO) trafficking and
    localization to the cilia. GLI mediators are in complex with proteins, including
    protein kinase A (PKA) and suppressor of fused homolog (SUFU), and generate repressor
    GLI forms, which translocate to the nucleus and inhibit transcription of HH signaling
    target genes; (B) In the presence of HH ligand, ligand binding to PTCH1 leads
    to PTCH1 internalization and degradation, SMO can traffic to the cilium and initiate
    a signaling cascade that processes the GLI proteins into transcriptional activator
    forms, which translocate to the nucleus and activate the expression of HH signaling
    target genes; (C) Activation of GLI1 and GLI2 in breast cancer by non-canonical
    pathways. Regulatory signaling cascades or regulatory proteins other than canonical
    Hedgehog signaling can modulate GLI1 and GLI2 expression, transcriptional activity
    and stability. Transforming growth factor β/transforming growth factor receptor
    (TGFβ/TGFR) signals can induce transcriptional up-regulation of GLI1 and GLI2
    via SMAD. Receptor tyrosine kinases (RTK) signals via the PI3K-AKT signaling cascade
    can induce stabilization of the GLI1 protein. In ERα-positive breast cancer cells
    E2 induces expression of SHH and GLI1 independent of SMO activity. WNT signaling
    activation stimulates GLI2. GLI2 ACT, the activator form of GLI2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Gli
  - ci
  - hh
  - Su(fu)
  - smo
  - sm
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - de
  - sna
  - 'On'
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Tie
  - Ras85D
  - InR
  - Jag
  - Dl
  - .na.character
  - Tapdelta
  - deltaTry
  - dpp
  - gbb
  - put
  - mav
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Raf
  - fz
  - Akt
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - Erk7
  - rl
  - Med
  - Smox
  - Mad
  - oo
  - act
  - Act5C
  - Act42A
  - Actbeta
  - DHH
  - IHH
  - SHH
  - GLI1
  - SUFU
  - GLI3
  - PTCH1
  - HHIP
  - SMO
  - SMOX
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - DDX50
  - SNAI1
  - GLI2
  - PSMB6
  - YY1
  - DLL1
  - TGFB1
  - TGFB2
  - TGFB3
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - SMAD3
  - SMAD4
  - SMAD1
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - SMAD2
  - SERPINA3
  - ACTG1
  - ACTG2
  - FHL5
  - ACOT7
  - ACTBL2
  - POTEKP
  - POTEM
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
